SCHEMBL5153773

SCHEMBL5153773

CCOC(=O)c1ccc(OC(C)NCCC(=O)Cc2ccc(N(C(N)=O)c3ccccc3F)c(OC)c2)c(OC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 3/20 0.41
▸ MAPT P10636 8/20 0.39
▸ ALDH1A1 P00352 4/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ TP53 P04637 1/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ KDM4E B2RXH2 3/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ ADRB2 P07550 5/20 0.36
▸ ADRB1 P08588 4/20 0.36
▸ ADRB3 P13945 4/20 0.36
▸ CYP3A4 P08684 2/20 0.35
▸ HTR1A P08908 1/20 0.35
▸ ADRA2A P08913 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ CHRM1 P11229 1/20 0.35
▸ DRD2 P14416 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6967330 0.93 GAA (0.42) GAAMAPTALDH1A1MAPK1TP53
SCHEMBL5153781 0.86 GAA (0.41) GAAMAPTALDH1A1TP53NPC1
SCHEMBL5153451 0.82 MAPT (0.42) GAAMAPTALDH1A1MAPK1TP53
SCHEMBL6967325 0.78 GAA (0.42) GAAMAPTALDH1A1TP53NPC1
SCHEMBL5151711 0.77 ITGA4 (0.47) GAAMAPTALDH1A1MAPK1TP53
SCHEMBL7137851 0.77 GAA (0.41) GAAMAPTALDH1A1MAPK1TP53
Methylamine SCHEMBL7137858 0.77 GAA (0.41) GAAMAPTALDH1A1MAPK1TP53
SCHEMBL6207583 0.77 ALDH1A1 (0.37) GAAMAPTALDH1A1MAPK1NPC1
SCHEMBL6960354 0.75 TDP1 (0.36) GAAMAPTALDH1A1MAPK1TP53
SCHEMBL5155538 0.74 C5AR1 (0.37) MAPTALDH1A1TP53NPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7179819-B2 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2007-02-20 — — US disclosed
US-20040229858-A1 VLA-4 inhibitor compounds DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-11-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229858-A1 VLA-4 inhibitor compounds VCAM1, ICAM1, ITGB4 GAA 1727/4885MAPT 3414/4885ALDH1A1 135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback